Vitamin B6 on Relieving Linezolid-associated Cytopenias
Recruitment status was Recruiting
Linezolid is the first approved synthetic oxazolidinone that is active against multidrug-resistant Gram-positive pathogens. Because of its significant efficacy, linezolid is widely used in clinical treatment. However, the side effects of linezolid commonly lead to anemia and thrombocytopenia. This hematological toxic effects limit its prolonged used. The investigators have found that Vitamin B6 application, as a preventive, auxiliary therapy, can relieve anemia and thrombocytopenia. The present study was designed to verify the effects of Vitamin B6 in the prevention of linezolid-associated cytopenias and investigate its mechanism.
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||The Effects and Mechanism of Vitamin B6 on Relieving Linezolid-associated Cytopenias|
|Study Start Date:||November 2010|
|Estimated Study Completion Date:||September 2011|
|Estimated Primary Completion Date:||July 2011 (Final data collection date for primary outcome measure)|
Infected patients receiving linezolid therapy are divided into two groups, i.e. the linezolid group and the linezolid + vitamin B6 group, the line of division being whether vitamin B6 is to be applied or not in the course of treatment. The purpose is to evaluate the role that vitamin B6 plays, during the process of linezolid therapy, in the relief of erythropenia and cytopenias.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01295801
|Contact: Su Longxiang, Doctor||+86 13621086327|
|Chinese PLA General Hospital||Recruiting|
|Beijing, Beijing, China, 100853|
|Study Director:||Xie Lixin, Doctor||Pneumology Department of chinese PLA General Hospital|